Endometrial Polyps Regression With Progesterone Therapy

Endometrial Polyp Clinical Trial

Official title: Efficacy of Subcutaneous Progesterone in Premenopausal Woman With Endometrial Polyp: a Multicentric Randomized Control Trial

Status Recruiting

Clinical Trial Summary

This prospective randomized study will compare the regression rates of women managed with watch-and-wait approach and of those treated with 3 cycles of luteal 25mg subcutaneous progesterone from 18 to 25 days of menstrual cycle

Clinical Trial Description

In premenopause, 25% of endometrial polyps regresses spontaneously in 1 year. According to guidelines, given that most premenopausal polyps are not malignant, there is an option for expectant approach with no surgical intervention. Studies on the efficacy of medical treatments for endometrial polyps are also recommended by gynaecologic societies, with the aim of finding cost-saving not invasive strategies to manage this common pathology. Up to now, nobody has investigated the effect of progestin administration on polyps, but molecular and clinical data suggest that the antiestrogenic effect of this hormone can be exploited to increase and speed-up their regression rate. Our preliminary results on the effect of three months of progesterone demonstrated a regression rate of 47,5% in women treated vs 12,5% in those don't receiving treatment.

Accordingly, in this prospective randomized study we aim to compare the regression rates of women managed with watch-and-wait approach and of those treated with 3 cycles of luteal 25mg subcutaneous progesterone from 18 to 25 days of menstrual cycle ;

Related Conditions & MeSH terms

• Endometrial Polyp
• Polyps
• Uterine Neoplasms

• NCT number: NCT03309709
• Study type: Interventional
• Source: University Magna Graecia
• Contact: Roberta Venturella, MD
• Phone: +390961883234
• Email: venturella@unicz.it
• Status: Recruiting
• Phase: Phase 3
• Start date: October 8, 2017
• Completion date: December 30, 2019